BG Medicine, Inc.  

(Public, NASDAQ:BGMD)   Watch this stock  
Find more results for BGMD
+0.013 (4.10%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.30 - 0.35
52 week 0.27 - 2.42
Open 0.31
Vol / Avg. 98,689.00/231,942.00
Mkt cap 11.40M
P/E     -
Div/yield     -
EPS -0.27
Shares 34.53M
Beta 2.91
Inst. own 45%
Mar 18, 2015
Q4 2014 BG Medicine Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Nov 13, 2014
Q3 2014 BG Medicine Inc Earnings Release
Nov 13, 2014
Q3 2014 BG Medicine Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -344.89% -389.12%
Operating margin -321.30% -352.91%
EBITD margin - -348.81%
Return on average assets -102.22% -128.89%
Return on average equity -338.65% -
Employees 23 -
CDP Score - -


United States - Map
+1-781-8901199 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BG Medicine, Inc. (BG Medicine) is a life sciences company focused on the discovery, development and commercialization of cardiovascular diagnostics to addresses unmet medical needs. The Company focuses on blood-based tests. Its lead product candidate in development is CardioSCORE, which is a multi-analyte biomarker-based blood test for atherothrombotic cardiovascular disease, commonly known as vulnerable plaque. In March 2011, the Company entered into a supply agreement with Health Diagnostic Laboratory, Inc. (HDL), pursuant to which HDL agreed to purchase manual galectin-3 test kits from the Company and to offer galectin-3 testing services to physicians in the United States. This manual version of Its Galectin-3 test is being marketed in the United States through a number of regional and national laboratory testing facilities. In addition, it has partnered with four diagnostic instrument manufacturers, which are developing automated instrument versions of its galectin-3 test.

Officers and directors

Stephane Bancel Chairman of the Board
Age: 41
Bio & Compensation  - Reuters
Paul R. Sohmer M.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Stephen P. Hall Chief Financial Officer, Executive Vice President, Treasurer
Age: 63
Bio & Compensation  - Reuters
Aram Adourian Ph.D. Senior Vice President, Chief Scientific Officer
Age: 44
Bio & Compensation  - Reuters
Noubar B. Afeyan Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Harrison M. Bains Jr. Independent Director
Age: 70
Bio & Compensation  - Reuters
Timothy Harris Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Stelios B. Papadopoulos Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Brian S Posner Independent Director
Age: 52
Bio & Compensation  - Reuters